메뉴 건너뛰기




Volumn 11, Issue , 2015, Pages 1767-1777

Profile of secukinumab in the treatment of psoriasis: Current perspectives

Author keywords

Biologics; IL 17; Psoriatic arthritis

Indexed keywords

ETANERCEPT; INTERLEUKIN 17; SECUKINUMAB; USTEKINUMAB;

EID: 84949750077     PISSN: 11766336     EISSN: 1178203X     Source Type: Journal    
DOI: 10.2147/TCRM.S79053     Document Type: Review
Times cited : (23)

References (40)
  • 2
    • 14244260176 scopus 로고    scopus 로고
    • Psoriatic arthritis: Epidemiology, clinical features, course, and outcome
    • Gladman DD, Antoni C, Mease P, Clegg DO, Nash P. Psoriatic arthritis: epidemiology, clinical features, course, and outcome. Ann Rheum Dis. 2005;64(Suppl 2):ii14-ii17.
    • (2005) Ann Rheum Dis. , vol.64 , pp. ii14-ii17
    • Gladman, D.D.1    Antoni, C.2    Mease, P.3    Clegg, D.O.4    Nash, P.5
  • 3
    • 27644565806 scopus 로고    scopus 로고
    • Serum levels of TNF-alpha, IFN-gamma, IL-6, IL-8, IL-12, IL-17, and IL-18 in patients with active psoriasis and correlation with disease severity
    • Arican O, Aral M, Sasmaz S, Ciragil P. Serum levels of TNF-alpha, IFN-gamma, IL-6, IL-8, IL-12, IL-17, and IL-18 in patients with active psoriasis and correlation with disease severity. Mediators Inflamm. 2005;2005(5):273-279.
    • (2005) Mediators Inflamm. , vol.2005 , Issue.5 , pp. 273-279
    • Arican, O.1    Aral, M.2    Sasmaz, S.3    Ciragil, P.4
  • 4
    • 70349753261 scopus 로고    scopus 로고
    • Th17 cytokines stimulate CCL20 expression in keratinocytes in vitro and in vivo: Implications for psoriasis pathogenesis
    • Harper EG, Guo C, Rizzo H, et al. Th17 cytokines stimulate CCL20 expression in keratinocytes in vitro and in vivo: implications for psoriasis pathogenesis. J Invest Dermatol. 2009;129(9):2175-2183.
    • (2009) J Invest Dermatol. , vol.129 , Issue.9 , pp. 2175-2183
    • Harper, E.G.1    Guo, C.2    Rizzo, H.3
  • 5
    • 77958460117 scopus 로고    scopus 로고
    • Paneth cells and innate mucosal immunity
    • Ouellette AJ. Paneth cells and innate mucosal immunity. Curr Opin Gastroenterol. 2010;26(6):547-553.
    • (2010) Curr Opin Gastroenterol. , vol.26 , Issue.6 , pp. 547-553
    • Ouellette, A.J.1
  • 6
    • 34548133583 scopus 로고    scopus 로고
    • Development, cytokine profile and function of human interleukin 17-producing helper T cells
    • Wilson NJ, Boniface K, Chan JR, et al. Development, cytokine profile and function of human interleukin 17-producing helper T cells. Nat Immunol. 2007;8(9):950-957.
    • (2007) Nat Immunol. , vol.8 , Issue.9 , pp. 950-957
    • Wilson, N.J.1    Boniface, K.2    Chan, J.R.3
  • 7
    • 5644277476 scopus 로고    scopus 로고
    • Interleukin-17 family members and inflammation
    • Kolls JK, Lindén A. Interleukin-17 family members and inflammation. Immunity. 2004;21(4):467-476.
    • (2004) Immunity. , vol.21 , Issue.4 , pp. 467-476
    • Kolls, J.K.1    Lindén, A.2
  • 8
    • 77958072084 scopus 로고    scopus 로고
    • Effects of AIN457, a fully human antibody to interleukin-17A, on psoriasis, rheumatoid arthritis, and uveitis
    • Hueber W, Patel DD, Dryja T, et al. Effects of AIN457, a fully human antibody to interleukin-17A, on psoriasis, rheumatoid arthritis, and uveitis. Sci Transl Med. 2010;2(52):52-72.
    • (2010) Sci Transl Med. , vol.2 , Issue.52 , pp. 52-72
    • Hueber, W.1    Patel, D.D.2    Dryja, T.3
  • 9
    • 84954386912 scopus 로고    scopus 로고
    • Long-term effects of secukinumab on MRI findings in relation to clinical efficacy in subjects with active ankylosing spondylitis: An observational study
    • Epub August 6
    • Baraliakos X, Borah B, Braun J. Long-term effects of secukinumab on MRI findings in relation to clinical efficacy in subjects with active ankylosing spondylitis: an observational study. Ann Rheum Dis. Epub August 6, 2015.
    • (2015) Ann Rheum Dis.
    • Baraliakos, X.1    Borah, B.2    Braun, J.3
  • 10
    • 84928829789 scopus 로고    scopus 로고
    • Efficacy and safety of intravenous secukinumab in noninfectious uveitis requiring steroid-sparing immunosuppressive therapy
    • Letko E, Yeh S, Foster CS, et al. Efficacy and safety of intravenous secukinumab in noninfectious uveitis requiring steroid-sparing immunosuppressive therapy. Ophthalmology. 2015;122(5):939-948.
    • (2015) Ophthalmology. , vol.122 , Issue.5 , pp. 939-948
    • Letko, E.1    Yeh, S.2    Foster, C.S.3
  • 11
    • 84887992906 scopus 로고    scopus 로고
    • Anti-interleukin-17A monoclonal antibody secukinumab in treatment of ankylosing spondylitis: A randomised, double-blind, placebo-controlled trial
    • Baeten D, Baraliakos X, Braun J, et al. Anti-interleukin-17A monoclonal antibody secukinumab in treatment of ankylosing spondylitis: a randomised, double-blind, placebo-controlled trial. Lancet. 2013;382(9906):1705-1713.
    • (2013) Lancet. , vol.382 , Issue.9906 , pp. 1705-1713
    • Baeten, D.1    Baraliakos, X.2    Braun, J.3
  • 12
    • 84877603562 scopus 로고    scopus 로고
    • Efficacy and safety of secukinumab in patients with rheumatoid arthritis: A phase II, dose-finding, double-blind, randomised, placebo controlled study
    • Genovese MC, Durez P, Richards HB, et al. Efficacy and safety of secukinumab in patients with rheumatoid arthritis: a phase II, dose-finding, double-blind, randomised, placebo controlled study. Ann Rheum Dis. 2013;72(6):863-869.
    • (2013) Ann Rheum Dis. , vol.72 , Issue.6 , pp. 863-869
    • Genovese, M.C.1    Durez, P.2    Richards, H.B.3
  • 13
    • 84923302849 scopus 로고    scopus 로고
    • Emerging drugs for the treatment of axial and peripheral spondyloarthritis
    • Braun J, Kiltz U, Heldmann F, Baraliakos X. Emerging drugs for the treatment of axial and peripheral spondyloarthritis. Expert Opin Emerg Drugs. 2015;20(1):1-14.
    • (2015) Expert Opin Emerg Drugs. , vol.20 , Issue.1 , pp. 1-14
    • Braun, J.1    Kiltz, U.2    Heldmann, F.3    Baraliakos, X.4
  • 14
    • 84868680312 scopus 로고    scopus 로고
    • Secukinumab, a human anti-IL-17A monoclonal antibody, for moderate to severe Crohn's disease: Unexpected results of a randomised, double-blind placebo-controlled trial
    • Hueber W, Sands BE, Lewitzky S, et al. Secukinumab, a human anti-IL-17A monoclonal antibody, for moderate to severe Crohn's disease: unexpected results of a randomised, double-blind placebo-controlled trial. Gut. 2012;61(12):1693-1700.
    • (2012) Gut. , vol.61 , Issue.12 , pp. 1693-1700
    • Hueber, W.1    Sands, B.E.2    Lewitzky, S.3
  • 15
    • 79960720836 scopus 로고    scopus 로고
    • [Revised January 1, 2015]. Accessed February 23, 2015
    • Highlights of Prescribing Information [Revised January 1, 2015]. Available from: http://www.pharma.us.novartis.com/product/pi/pdf/cosentyx.pdf. Accessed February 23, 2015.
    • Highlights of Prescribing Information
  • 16
    • 84922933349 scopus 로고    scopus 로고
    • Secukinumab administration by pre-filled syringe: Efficacy, safety and usability results from a randomized controlled trial in psoriasis (FEATURE)
    • Blauvelt A, Prinz JC, Gottlieb AB, et al. Secukinumab administration by pre-filled syringe: efficacy, safety and usability results from a randomized controlled trial in psoriasis (FEATURE). Br J Dermatol. 2015;172(2):484-493.
    • (2015) Br J Dermatol. , vol.172 , Issue.2 , pp. 484-493
    • Blauvelt, A.1    Prinz, J.C.2    Gottlieb, A.B.3
  • 17
    • 84929629144 scopus 로고    scopus 로고
    • Efficacy, safety and usability of secukinumab administration by autoinjector/pen in psoriasis: A randomized, controlled trial (JUNCTURE)
    • Paul C, Lacour JP, Tedremets L, et al. Efficacy, safety and usability of secukinumab administration by autoinjector/pen in psoriasis: a randomized, controlled trial (JUNCTURE). J Eur Acad Dermatol Venereol. 2015;29(6):1082-1090.
    • (2015) J Eur Acad Dermatol Venereol. , vol.29 , Issue.6 , pp. 1082-1090
    • Paul, C.1    Lacour, J.P.2    Tedremets, L.3
  • 18
    • 54249138516 scopus 로고    scopus 로고
    • Monoclonal antibody pharmacokinetics and pharmacodynamics
    • Wang W, Wang EQ, Balthasar JP. Monoclonal antibody pharmacokinetics and pharmacodynamics. Clin Pharmacol Ther. 2008; 84(5):548-558.
    • (2008) Clin Pharmacol Ther. , vol.84 , Issue.5 , pp. 548-558
    • Wang, W.1    Wang, E.Q.2    Balthasar, J.P.3
  • 19
    • 84897954122 scopus 로고    scopus 로고
    • Secukinumab treatment in rheumatoid arthritis is associated with incremental benefit in the clinical outcomes and HRQoL improvements that exceed minimally important thresholds
    • Strand V, Kosinski M, Gnanasakthy A, Mallya U, Mpofu S. Secukinumab treatment in rheumatoid arthritis is associated with incremental benefit in the clinical outcomes and HRQoL improvements that exceed minimally important thresholds. Health Qual Life Outcomes. 2014;12:31.
    • (2014) Health Qual Life Outcomes. , vol.12 , pp. 31
    • Strand, V.1    Kosinski, M.2    Gnanasakthy, A.3    Mallya, U.4    Mpofu, S.5
  • 20
    • 84873124241 scopus 로고    scopus 로고
    • Efficacy and safety of secukinumab in the treatment of moderate-to-severe plaque psoriasis: A randomized, double-blind, placebo-controlled phase II dose-ranging study
    • Papp KA, Langley RG, Sigurgeirsson B, et al. Efficacy and safety of secukinumab in the treatment of moderate-to-severe plaque psoriasis: a randomized, double-blind, placebo-controlled phase II dose-ranging study. Br J Dermatol. 2013;168(2):412-421.
    • (2013) Br J Dermatol. , vol.168 , Issue.2 , pp. 412-421
    • Papp, K.A.1    Langley, R.G.2    Sigurgeirsson, B.3
  • 21
    • 84873168729 scopus 로고    scopus 로고
    • Secukinumab induction and maintenance therapy in moderate-to-severe plaque psoriasis: A randomized, double-blind, placebo-controlled, phase II regimen-finding study
    • Rich P, Sigurgeirsson B, Thaci D, et al. Secukinumab induction and maintenance therapy in moderate-to-severe plaque psoriasis: a randomized, double-blind, placebo-controlled, phase II regimen-finding study. Br J Dermatol. 2013;168(2):402-411.
    • (2013) Br J Dermatol. , vol.168 , Issue.2 , pp. 402-411
    • Rich, P.1    Sigurgeirsson, B.2    Thaci, D.3
  • 22
    • 84937972700 scopus 로고    scopus 로고
    • Secukinumab retreatment-as-needed versus fixed-interval maintenance regimen for moderate to severe plaque psoriasis: A randomized, double-blind, noninferiority trial (SCULPTURE)
    • Mrowietz U, Leonardi CL, Girolomoni G, et al. Secukinumab retreatment-as-needed versus fixed-interval maintenance regimen for moderate to severe plaque psoriasis: a randomized, double-blind, noninferiority trial (SCULPTURE). J Am Acad Dermatol. 2015;73(1): 27-36.e1.
    • (2015) J Am Acad Dermatol. , vol.73 , Issue.1
    • Mrowietz, U.1    Leonardi, C.L.2    Girolomoni, G.3
  • 23
    • 84904545875 scopus 로고    scopus 로고
    • Secukinumab in plaque psoriasis - results of two phase 3 trials
    • Langley RG, Elewski BE, Lebwohl M, et al. Secukinumab in plaque psoriasis - results of two phase 3 trials. N Engl J Med. 2014;371(4):326-338.
    • (2014) N Engl J Med. , vol.371 , Issue.4 , pp. 326-338
    • Langley, R.G.1    Elewski, B.E.2    Lebwohl, M.3
  • 25
    • 84915805860 scopus 로고    scopus 로고
    • Secukinumab efficacy and safety in Japanese patients with moderate-to-severe plaque psoriasis: Subanalysis from ERASURE, a randomized, placebo-controlled, phase 3 study
    • Ohtsuki M, Morita A, Abe M, et al. Secukinumab efficacy and safety in Japanese patients with moderate-to-severe plaque psoriasis: subanalysis from ERASURE, a randomized, placebo-controlled, phase 3 study. J Dermatol. 2014;41(12):1039-1046.
    • (2014) J Dermatol. , vol.41 , Issue.12 , pp. 1039-1046
    • Ohtsuki, M.1    Morita, A.2    Abe, M.3
  • 26
    • 84939463415 scopus 로고    scopus 로고
    • Secukinumab is superior to ustekinumab in clearing skin of subjects with moderate to severe plaque psoriasis: CLEAR, a randomized controlled trial
    • Thaçi D, Blauvelt A, Reich K, et al. Secukinumab is superior to ustekinumab in clearing skin of subjects with moderate to severe plaque psoriasis: CLEAR, a randomized controlled trial. J Am Acad Dermatol. 2015;73(3):400-409.
    • (2015) J Am Acad Dermatol. , vol.73 , Issue.3 , pp. 400-409
    • Thaçi, D.1    Blauvelt, A.2    Reich, K.3
  • 27
    • 84937984975 scopus 로고    scopus 로고
    • Secukinumab in psoriasis: Randomized, controlled phase 3 trial results assessing the potential to improve treatment response in partial responders (STATURE)
    • Thaçi D, Humeniuk J, Frambach Y, et al. Secukinumab in psoriasis: randomized, controlled phase 3 trial results assessing the potential to improve treatment response in partial responders (STATURE). Br J Dermatol. 2015;173(3):777-787.
    • (2015) Br J Dermatol. , vol.173 , Issue.3 , pp. 777-787
    • Thaçi, D.1    Humeniuk, J.2    Frambach, Y.3
  • 28
    • 84891740105 scopus 로고    scopus 로고
    • Efficacy and safety of secukinumab, a fully human anti-interleukin-17A monoclonal antibody, in patients with moderate-to-severe psoriatic arthritis: A 24-week, randomised, double-blind, placebo-controlled, phase II proof-of-concept trial
    • McInnes IB, Sieper J, Braun J, et al. Efficacy and safety of secukinumab, a fully human anti-interleukin-17A monoclonal antibody, in patients with moderate-to-severe psoriatic arthritis: a 24-week, randomised, double-blind, placebo-controlled, phase II proof-of-concept trial. Ann Rheum Dis. 2014;73(2):349-356.
    • (2014) Ann Rheum Dis. , vol.73 , Issue.2 , pp. 349-356
    • McInnes, I.B.1    Sieper, J.2    Braun, J.3
  • 29
    • 84942891597 scopus 로고    scopus 로고
    • Secukinumab inhibition of interleukin-17a in patients with psoriatic arthritis
    • Mease PJ, McInnes IB, Kirkham B. Secukinumab inhibition of interleukin-17a in patients with psoriatic arthritis. N Engl J Med. 2015;373(14):1329-1339.
    • (2015) N Engl J Med. , vol.373 , Issue.14 , pp. 1329-1339
    • Mease, P.J.1    McInnes, I.B.2    Kirkham, B.3
  • 30
    • 84942198180 scopus 로고    scopus 로고
    • Secukinumab, a human anti-interleukin-17A monoclonal antibody, in patients with psoriatic arthritis (FUTURE 2): A randomised, double-blind, placebo-controlled, phase 3 trial
    • McInnes IB, Mease PJ, Kirkham B, et al. Secukinumab, a human anti-interleukin-17A monoclonal antibody, in patients with psoriatic arthritis (FUTURE 2): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2015;386(9999):1137-1146.
    • (2015) Lancet. , vol.386 , Issue.9999 , pp. 1137-1146
    • McInnes, I.B.1    Mease, P.J.2    Kirkham, B.3
  • 31
    • 84949759880 scopus 로고    scopus 로고
    • Secukinumab improves physical function in subjects with plaque psoriasis and psoriatic arthritis: Results from two randomized, phase 3 trials
    • Gottlieb AB, Langley RG, Philipp S, et al. Secukinumab improves physical function in subjects with plaque psoriasis and psoriatic arthritis: results from two randomized, phase 3 trials. J Drugs Dermatol. 2015;14(8):821-833.
    • (2015) J Drugs Dermatol. , vol.14 , Issue.8 , pp. 821-833
    • Gottlieb, A.B.1    Langley, R.G.2    Philipp, S.3
  • 32
    • 3242814586 scopus 로고    scopus 로고
    • Requirement of interleukin-17A for systemic anti-Candida albicans host defense in mice
    • Huang W, Na L, Fidel PL, Schwarzenberger P. Requirement of interleukin-17A for systemic anti-Candida albicans host defense in mice. J Infect Dis. 2004;190(3):624-631.
    • (2004) J Infect Dis. , vol.190 , Issue.3 , pp. 624-631
    • Huang, W.1    Na, L.2    Fidel, P.L.3    Schwarzenberger, P.4
  • 33
    • 84938884415 scopus 로고    scopus 로고
    • Immunogenicity of biologic treatments for psoriasis: Therapeutic consequences and the potential value of concomitant methotrexate
    • Farhangian ME, Feldman SR. Immunogenicity of biologic treatments for psoriasis: therapeutic consequences and the potential value of concomitant methotrexate. Am J Clin Dermatol. 2015;16(4):285-294.
    • (2015) Am J Clin Dermatol. , vol.16 , Issue.4 , pp. 285-294
    • Farhangian, M.E.1    Feldman, S.R.2
  • 34
    • 33746925234 scopus 로고    scopus 로고
    • IL-17A-producing neutrophil-regulatory Tn lymphocytes
    • Ley K, Smith E, Stark MA. IL-17A-producing neutrophil-regulatory Tn lymphocytes. Immunol Res. 2006;34(3):229-242.
    • (2006) Immunol Res. , vol.34 , Issue.3 , pp. 229-242
    • Ley, K.1    Smith, E.2    Stark, M.A.3
  • 35
    • 84867247301 scopus 로고    scopus 로고
    • Treatment with the interleukin-17A-blocking antibody secukinumab does not interfere with the efficacy of influenza and meningococcal vaccinations in healthy subjects: Results of an open-label, parallel-group, randomized single-center study
    • Chioato A, Noseda E, Stevens M, Gaitatzis N, Kleinschmidt A, Picaud H. Treatment with the interleukin-17A-blocking antibody secukinumab does not interfere with the efficacy of influenza and meningococcal vaccinations in healthy subjects: results of an open-label, parallel-group, randomized single-center study. Clin Vaccine Immunol. 2012;19(10):1597-1602.
    • (2012) Clin Vaccine Immunol. , vol.19 , Issue.10 , pp. 1597-1602
    • Chioato, A.1    Noseda, E.2    Stevens, M.3    Gaitatzis, N.4    Kleinschmidt, A.5    Picaud, H.6
  • 36
    • 84859073115 scopus 로고    scopus 로고
    • Anti-interleukin-17 monoclonal antibody ixekizumab in chronic plaque psoriasis
    • Leonardi C, Matheson R, Zachariae C, et al. Anti-interleukin-17 monoclonal antibody ixekizumab in chronic plaque psoriasis. N Engl J Med. 2012;366(13):1190-1199.
    • (2012) N Engl J Med. , vol.366 , Issue.13 , pp. 1190-1199
    • Leonardi, C.1    Matheson, R.2    Zachariae, C.3
  • 37
    • 84859017988 scopus 로고    scopus 로고
    • Brodalumab, an anti-interleukin-17-receptor antibody for psoriasis
    • Papp KA, Leonardi C, Menter A, et al. Brodalumab, an anti-interleukin-17-receptor antibody for psoriasis. N Engl J Med. 2012;366(13):1181-1189.
    • (2012) N Engl J Med. , vol.366 , Issue.13 , pp. 1181-1189
    • Papp, K.A.1    Leonardi, C.2    Menter, A.3
  • 38
    • 84938992082 scopus 로고    scopus 로고
    • Comparison of ixekizumab with etanercept or placebo in moderate-to-severe psoriasis (UNCOVER-2 and UNCOVER-3): Results from two phase 3 randomised trials
    • Griffiths CE, Reich K, Lebwohl M, et al. Comparison of ixekizumab with etanercept or placebo in moderate-to-severe psoriasis (UNCOVER-2 and UNCOVER-3): results from two phase 3 randomised trials. Lancet. 2015;386(9993):541-551.
    • (2015) Lancet. , vol.386 , Issue.9993 , pp. 541-551
    • Griffiths, C.E.1    Reich, K.2    Lebwohl, M.3
  • 39
    • 84933035939 scopus 로고    scopus 로고
    • Interleukin-17 antagonists in the treatment of psoriasis
    • Chandrakumar SF, Yeung J. Interleukin-17 antagonists in the treatment of psoriasis. J Cutan Med Surg. 2015;19(2):109-114.
    • (2015) J Cutan Med Surg. , vol.19 , Issue.2 , pp. 109-114
    • Chandrakumar, S.F.1    Yeung, J.2
  • 40
    • 84922410788 scopus 로고    scopus 로고
    • Inhibition of interleukin-17, interleukin-23 and the TH17 cell pathway in the treatment of psoriatic arthritis and psoriasis
    • Mease PJ. Inhibition of interleukin-17, interleukin-23 and the TH17 cell pathway in the treatment of psoriatic arthritis and psoriasis. Curr Opin Rheumatol. 2015;27(2):127-133.
    • (2015) Curr Opin Rheumatol. , vol.27 , Issue.2 , pp. 127-133
    • Mease, P.J.1


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.